



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 29th January, 2019

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. 29th January, 2019

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. 29th January, 2019 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results for the quarter and Nine Month ended on 31st December, 2018.

Please find enclosed Unaudited Standalone and Consolidated Financial Results for the quarter and Nine Month ended on 31st December, 2018 along with the Limited Review Reports of the Auditors.

The meeting of the Board of Directors commenced at 11:45 am. and concluded at 15:20 pm.

This is for your information and record.

Thanking You.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED
(Formerly Known as Eris Lifesciences Private Limited)**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Company"), for the Quarter and Nine Months ended December 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in blue ink, appearing to read "Gaurav J. Shah".

Gaurav J. Shah
Partner
(Membership No. 35701)

Ahmedabad, January 29, 2019



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

Particulars	[Rs. in Million except per share data]					
	For Quarter Ended			For Nine Months Ended		For Year Ended
	December 31, 2018 (Unaudited)	September 30, 2018 (Unaudited)	December 31, 2017 (Unaudited)	December 31, 2018 (Unaudited)	December 31, 2017 (Unaudited)	March 31, 2018 (Audited)
Revenue from Operations						
Sale of products	2,267.61	2,370.74	1,806.71	6,865.16	5,423.68	7,323.36
Other operating income	40.42	37.37	15.37	115.93	241.59	282.65
Total Revenue from Operations	2,308.03	2,408.11	1,822.08	6,981.09	5,665.27	7,606.01
Other Income	101.54	62.39	60.16	208.99	200.21	282.23
Total Income	2,409.57	2,470.50	1,882.24	7,190.08	5,865.48	7,888.24
Expenses						
Cost of materials consumed	199.01	133.29	114.41	466.44	345.55	470.79
Purchase of stock-in-trade	246.15	213.11	320.59	580.83	481.65	648.90
Changes in inventories of Finished goods, Work-in-Progress and Stock-in-trade	(107.75)	6.19	(171.46)	(27.24)	(29.19)	(35.43)
Employee Benefits Expense	416.62	405.84	352.25	1,257.28	951.54	1,308.45
Finance Costs	50.94	62.40	27.06	184.10	27.06	104.29
Depreciation and Amortisation Expense	83.93	70.75	56.09	215.54	140.23	217.92
Other Expenses	647.99	679.04	414.13	1,986.39	1,478.50	2,054.43
Total Expenses	1,536.89	1,570.62	1,113.07	4,663.34	3,395.34	4,769.35
Profit before Tax	872.68	899.88	769.17	2,526.74	2,470.14	3,118.89
Tax Expense						
Current Tax	191.94	198.35	168.88	556.50	539.03	679.46
Deferred Tax	(108.03)	(138.31)	(138.86)	(359.41)	(430.48)	(497.12)
Total Tax Expense	83.91	60.04	30.02	197.09	108.55	182.34
Net Profit for the period	788.77	839.84	739.15	2,329.65	2,361.59	2,936.55
Other Comprehensive Income	0.33	0.99	(1.22)	0.99	(3.68)	(0.73)
Items that will not be reclassified to profit or loss	0.51	1.52	(1.87)	1.53	(5.63)	(1.12)
Income tax relating to items that will not be reclassified to profit or loss	(0.18)	(0.53)	0.65	(0.54)	1.95	0.39
Total Comprehensive Income	789.10	840.83	737.93	2,330.64	2,357.91	2,935.82
Paid Up Equity Share Capital (Face Value of Rs.1 each)	137.52	137.52	137.50	137.52	137.50	137.50
Other Equity						8,544.29
Earnings Per Share (of Rs. 1 each) (not annualised) :						
Basic	5.74	6.10	5.38	16.94	17.18	21.36
Diluted	5.74	6.10	5.38	16.93	17.18	21.36

See accompanying notes to the financial results



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 / 71841000
• Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial results

1. The above statement of financial results ("the Statement") of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on January 29, 2019. The Statutory Auditors of the Company have carried out Limited Review of the Statement.
2. The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
3. The Company has acquired Indian domestic formulation business of Strides Shasun Limited on a going concern basis by way of slump sale on November 30, 2017. Accordingly, figures for the current periods are not comparable with previous periods.
4. Revenue from operation upto June 30, 2017 was reported inclusive of excise duty which is now subsumed in Goods and Services Tax. Accordingly, figures of revenue from operations for the nine months ended December 31, 2018 are not comparable with the figures of the previous period.
5. Effective April 1, 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Company.
6. Figures for the previous periods have been regrouped wherever considered necessary.



Place: Ahmedabad
Date : January 29, 2019



For Eris Lifesciences Limited,

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ERIS LIFESCIENCES LIMITED (Formerly Known as Eris Lifesciences Private Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the Quarter and Nine Months ended December 31, 2018 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities:
 - i. Eris Lifesciences Limited (Parent)
 - ii. Aprica Healthcare Private Limited (Subsidiary)
 - iii. Kinedex Healthcare Private Limited (Subsidiary)
 - iv. Eris Therapeutics Private Limited (Subsidiary)
 - v. UTH Healthcare Limited (Subsidiary- From 1st October, 2017)
 - vi. Eris Healthcare Private Limited (Formerly known as Strides Healthcare Private Limited) (Subsidiary- From 1st December, 2017)



4. Based on our review conducted as stated above and based on the consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of all the 5 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 219.41 million and Rs. 712.74 million for the quarter and nine months ended December 31, 2018 respectively, total profit after tax of Rs. 18.31 million and Rs. 61.54 million and total comprehensive income of Rs. 18.58 million and Rs. 62.36 million for the quarter and nine months ended December 31, 2018 respectively, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in blue ink, appearing to read "Gaurav J. Shah", with a horizontal line underneath.

Gaurav J. Shah
Partner
(Membership No. 35701)

Ahmedabad, January 29, 2019



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

Particulars	[Rs. in Million except per share data]					
	For Quarter Ended			For Nine Months Ended		For Year Ended
	December 31, 2018 (Unaudited)	September 30, 2018 (Unaudited)	December 31, 2017 (Unaudited)	December 31, 2018 (Unaudited)	December 31, 2017 (Unaudited)	March 31, 2018 (Audited)
Revenue from Operations						
Sale of products	2,484.78	2,605.62	2,075.22	7,561.17	6,190.79	8,271.04
Other operating income	39.17	36.22	14.49	112.23	243.33	285.00
Total Revenue from Operations	2,523.95	2,641.84	2,089.71	7,673.40	6,434.12	8,556.04
Other Income	102.88	61.53	57.84	199.65	191.03	264.08
Total Income	2,626.83	2,703.37	2,147.55	7,873.05	6,625.15	8,820.12
Expenses						
Cost of materials consumed	199.01	133.29	114.41	466.44	345.55	470.79
Purchase of stock-in-trade	321.46	264.94	425.08	750.06	680.60	898.36
Changes in inventories of Finished goods, Work-in-Progress and Stock-in-trade	(126.55)	7.42	(202.80)	(28.27)	(15.12)	(28.53)
Employee Benefits Expense	474.52	468.95	428.19	1,434.28	1,157.40	1,573.22
Finance Costs	51.08	62.49	27.63	184.62	27.95	105.50
Depreciation and Amortisation Expense	95.92	82.80	66.85	251.47	165.78	256.42
Other Expenses	720.27	760.37	513.93	2,223.27	1,762.84	2,422.07
Total Expenses	1,735.71	1,780.26	1,373.29	5,281.87	4,125.00	5,697.83
Profit before Tax	891.12	923.11	774.26	2,591.18	2,500.15	3,122.29
Tax Expense						
Current Tax	198.01	204.59	169.19	578.08	548.36	687.93
Deferred Tax	(108.87)	(136.54)	(144.14)	(359.53)	(437.21)	(515.42)
Total Tax Expense	89.14	68.05	25.05	218.55	111.15	172.51
Net Profit for the period	801.98	855.06	749.21	2,372.63	2,389.00	2,949.78
Attributable to :						
- Owners of the Company	801.38	853.20	746.13	2,367.09	2,383.18	2,941.05
- Non controlling interest	0.60	1.86	3.08	5.54	5.82	8.73
Other Comprehensive Income	0.60	1.19	(1.20)	1.81	(3.62)	0.66
Items that will be reclassified to profit or loss	0.85	1.73	(1.85)	2.56	(5.57)	0.78
Income tax relating to items that will be reclassified to profit or loss	(0.25)	(0.54)	0.65	(0.75)	1.95	(0.12)
Total Comprehensive Income	802.58	856.25	748.01	2,374.44	2,385.38	2,950.44
Attributable to :						
- Owners of the Company	801.98	854.39	744.93	2,368.90	2,379.56	2,941.71
- Non controlling interest	0.60	1.86	3.08	5.54	5.82	8.73
Paid Up Equity Share Capital (Face Value of Rs.1 each)	137.52	137.52	137.50	137.52	137.50	137.50
Other Equity						8,475.57
Earnings Per Share (of Rs. 1 each) (not annualised) :						
Basic	5.83	6.20	5.43	17.21	17.33	21.39
Diluted	5.83	6.20	5.43	17.20	17.33	21.39
See accompanying notes to the financial results						



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India
 Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 / 71841000
 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial results

1. The above statement of financial results ("the Statement") of the Group were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on January 29, 2019. The Statutory Auditors of the Company have carried out Limited Review of the Statement.
2. The Group is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
3. The Group has acquired Indian domestic formulation business of Strides Shasun Limited on a going concern basis by way of slump sale on November 30, 2017. Accordingly, figures for the current periods are not comparable with previous periods.
4. Revenue from operation upto June 30, 2017 was reported inclusive of excise duty which is now subsumed in Goods and Services Tax. Accordingly, figures of revenue from operations for the nine months ended December 31, 2018 are not comparable with the figures of the previous period.

5. Information of Standalone Financial Result of the Company is as Under:


(Rs. in Million)

Particulars	Quarter Ended			Nine months Ended		Year Ended
	December 31, 2018 (unaudited)	Sept 30, 2018 (unaudited)	December 31, 2017 (unaudited)	December 31, 2018 (unaudited)	December 31, 2017 (unaudited)	March 31, 2018 (Audited)
Revenue from Operations	2,308.03	2,408.11	1,822.08	6,981.09	5,665.27	7,606.01
Profit Before Tax	872.68	899.88	769.17	2,526.74	2,470.14	3,118.89
Net Profit for the period	788.77	839.84	739.15	2,329.65	2,361.59	2,936.55

6. Effective April 1, 2018, the Group has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
7. Figures for the previous periods have been regrouped wherever considered necessary.



Place: Ahmedabad
Date : January 29, 2019



For Eris Lifesciences Limited,

Amit Bakshi
Chairman and Managing Director
DIN : 01250925